RealWorld Dynamix™: Biologic and Otezla Switching in PsA US 2017 Spotlight II

A recent sub-analysis of RealWorld Dynamix: Biologic and Otezla Switching in PsA, involving 1,008 PsA patients recently switched between biologic brands and/or Otezla reveals that 26% of recently switched PsA patients are either currently treated off-label with Xeljanz, will be switched to Xeljanz next if their current agent is unsuccessful, or are considered good candidates for Pfizer’s JAK, while one in five fit the same bill for treatment with the IL-17 inhibitor, Taltz.

Click the button below to view highlights from this report:

Download Report Spotlight